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List of abbreviations and sym bols
BCNU 1 y 3-bis(2-chloroethyl)-1 -nitrosourea (a
GSH-R inhibitor)
BHA butylated hydroxyanisole (a radical scav­
enger)
CM cerebral malaria
CD36 cluster of difference 36 (integral mem­
brane glycoprotein)
DFO desferrioxamine, deferoxamine, desferal
(a chelator)
ELAM-1 endothelial leukocyte adhesion molecule-
1
G6PD glucose-6-phosphate dehydrogenase 
CSH glutathione (reduced)
GSH-P glutathione peroxidase 
GSH-R glutathione reductase 
GSSG glutathione (oxidised)
HeCNU 1 -(2-ch)oroethyl)-3~(2-hydroxyethyl)-l -
nitrosourea (a GSH-R inhibitor)
HMS hexose monophosphate shunt 
HRP histidine-rich proteins 
ICAM-1 intercellular adhesion molecule-1 
IFN-g interferon-gamma (a cytokine)
11-1 interleukine-1 (a cytokine)
IRBC infected red blood cells 
NADPH nicotinamide-adenine-dinucleotide phos­
phate (reduced)
0 2*~ superoxide radical
*OH hydroxy! radical
P. Plasmodium
PE parasitised erythrocytes
PEG polyethylene glycol
PfEMPl Plasmodium falciparum erythrocyte major
protein 1
PMN's polymorphonuclear cells
R' secondary radical
ROS reactive oxygen species
SOD superoxide dismutase
TNF tumour necrosis factor (a cytokine)
VCAM-1 vascular adhesion molecule-1
Introduction
Malaria is an infectious disease, which world-wide 
affects more than 200 million people of which 1-2 mil­
lion die each year (mainly children) [1]. The increas­
ing and widespread resistance of parasites to the cur­
rent antimalarials (a.o. chloroquine) is a major prob­
lem in the prevention and treatment of this disease.
Malaria is caused by protozoan parasites belonging 
to the genus Plasmodium. Four Plasmodium species 
are able to infect humans. P. falciparum causes the 
most dangerous form of malaria and is life threaten­
ing in an unprotected, non-immune population [2-5]. 
The disease is transmitted by the bite of an infectious 
female mosquito. The parasites enter the blood 
stream, migrate to the liver and from there infect red 
blood cells. The parasite proliferates in red blood cells, 
and the released progeny invades new red cells. The
N.S. Postma, E C  Mommers, W .M.C Eling atidj. Zuidema. 
Oxidative Stress in Malaria; Implications for Prevention and 
Therapy.
Pharm World Sci 1996; 18(4): 121-129.
© 1996 Kluwer Academic Publishers. Printed in the 
Netherlands.
Postma NS*, Zuidema J, Department of Pharmaceutics, 
University of Utrecht, The Netherlands, Mommers EC,
Eling WMC, Department of Medical Microbiology, University 
Hospital Nijmegen, The Netherlands.
^(Corresponding author) Department of Pharmaceutics, 
University of Utrecht, Sorbonnelaan 16, PO Box 80082, 3508 
TB Utrecht, The Netherlands
Keywords
Oxidative stress 
Reactive oxygen species 
Malaria
Cerebral malaria 
Cytokines, Pro-oxidants 
Anti-oxidants, Artemisinin 
Desferrioxamine
Abstract
Malaria affects world-wide more than 200 million people, of 
which 1-2 million die every year. New drugs and treatment 
strategies are needed to face the rapidly increasing problems 
of drug resistance.
During a malaria infection, both host and parasite are 
under oxidative stress. Increased production levels of reactive 
oxygen species (ROS, e.g. superoxide anion and the hydroxyl 
radical) are produced by activated neutrophils in the host 
and during degradation of haemoglobin in the parasite.
The effects of ROS in malaria can be both beneficial and 
pathological, depending on the amount and place of 
production. Enhanced ROS production after the 
administration of pro-oxidants, which is directed against the 
intra-erythrocytic parasite, inhibits the infection both in vitro 
and in vivo. However, ROS are also involved in pathological 
changes in host tissue like damage of the vascular endothelial 
lining during a malaria infection (cerebral malaria).
Pro-oxidants support the host defense against the parasite 
when working in or near the infected cell but potentially 
cause vascular damage when working on or near the vascular 
lining. Examples of pro-oxidants are found among 
xenobiotics and food components. Important new drugs 
belonging to the class of pro-oxidants are artemisinin and its 
derivatives. Anti-oxidants potentially counteract these 
agents.
Treatment with anti-oxidants or chelators of metals to 
prevent their catalytic function in the generation of ROS may 
prevent vascular pathology. In addition, the iron chelator 
desferrioxamine, exhibits an antiparasitic activity, because 
iron is also essential for the proliferation of the parasite.
Cytokines play an important role in ROS-related pathology 
of malaria, though their mechanism of action is not 
completely elucidated. This field might bring up new 
treatment concepts and drugs.
Drugs which prevent host pathology, such as the cerebral 
complications might be life saving.
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erythrocytic cycle of the parasite causes the disease 
symptoms. For more details of the life cycle of the 
human malaria parasite, its differentiation and specific 
forms in the female mosquito and in the host the 
reader should refer to the literature [6].
A P. falciparum infection is characterised by an incu­
bation period of about 12 days. Clinical manifesta­
tions are a,o. intermittent fever (every 48 hours), 
severe anaemia, shock, cerebral involvement, pulmo­
nary oedema, hypoglycaemia and renal failure. Death 
occurs in 5-20% of patients that develop cerebral 
malaria. People that recover from cerebral malaria 
usually do not exhibit neurological sequellae (85% of 
children and 95% of adults) [4].
P, vivax and R ovale infections show respectively an 
incubation period of 13 and 17 or more days and 
again fever occurs every 48 hours. Other clinical man­
ifestations are chronic anaemia and persistent sple­
nomegaly.
The fourth parasite, P,: malariae, causes chronic, 
often low grade, infection. The malaria infection is 
common in localised areas in the tropics. This infec­
tion has an incubation period of 28 days or longer 
and fever occurs every 72 hours. The infection may 
persist for 50 years or more, but is often without seri­
ous morbidity.
Much effort has been put into research for new 
antimalarials and the development of vaccines against 
the most threatening parasite P. falciparum. The 
search for new antimalarials is impeded by the lack of 
knowledge of the pathogenesis of the disease. In the 
early 1950s, Gilbert suggested that reactive oxygen 
species (ROS) play an important role in many human 
pathologies and malaria seems to be one of them [7].
Reactive oxygen species (ROS) is a collective noun 
for oxidising compounds such as superoxide radical 
(0 2*'X hydrogen peroxide (H20 2), hydroxyl radical 
(*OH), lipid peroxides, and other related species [8]. 
They are produced as a physiological response to a 
specific noxa. During a malaria infection massively 
recruited and activated monocytes and neutrophils 
produce increasing levels of ROS (oxidative stress), alt­
hough other mechanisms are involved as well [9-11]. 
However oxidative stress during malaria is beneficial 
to the patient in the combat against its intra-erythro- 
cytic parasite. Several studies have been described in 
which induction of oxidative stress by treatment with 
pro-oxidants proved to be effective against the infec­
tion [reviewed in 12]. On the other hand ROS play a 
role in the pathology of malaria. Excessive oxidative 
stress and particularly at unwanted places (e.g. vascu­
lar lining, blood brain barrier) will damage the 
defense system. Intra- and extracellular anti-oxidant 
systems are present to prevent damage, but they may 
fail during disease. Treatment with anti-oxidants rein­
forces these systems and protect the patient, especial­
ly during the life threatening phase of the disease [13 
14].
An understanding of the role and mechanisms of 
action of oxidative stress may eventually lead to the 
development of new drugs and new concepts of 
treatment. This review will discuss oxidative stress and 
its role in malaria and also new strategies in the treat­
ment and drug development that are based on the 
knowledge of oxidative stress in malaria, in order to
prevent and to treat patients with this life threatening 
infection.
Principles of biosynthesis and biotransfor­
mation of ROS
The formation and biotransformation (detoxification) 
of ROS in biological systems is depicted in Figure 1. In 
this scheme the production of ROS is started when 
phagocytic cells are activated by immune modula­
tors. One of the consequences of activation of macro­
phages is the generation of a respiratory burst. 
During activation of the respiratory burst, oxygen is 
taken up by the membrane-bound NADPH-oxidase 
complex and reduced to the superoxide radical [IB- 
16].
Another process in which the 0 2*- is formed is the 
reduction of molecular oxygen in cells [15], not 
shown in Figure 1. The 0 2*~ is reduced by superoxide 
dismutase (SOD) to H20 2 and this in turn is reduced 
to water by glutathione peroxidase (GSH-P) or by cat- 
alase. The oxidised glutathione (GSSG) is rapidly 
reduced by glutathione reductase (GSH-R), utilising 
NADPH generated by various intracellular reactions, 
including the hexose monophosphate shunt (HMS) 
[13-15].
SOD, catalase and GSH-P/GSH-R are important 
intracellular anti-oxidant enzymes; they are, however, 
much less prominently present in extracellular fluids. 
Catalase is present in liver cells and erythrocytes at 
high concentrations. Its reactivity is important when 
H20 2 concentrations are raised.
The transformation of 0 2*' and H20 2 into the very
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Figure 1
Formation and biotransformation of ROS in biological
systems.
0 / ;  superoxide; SOD, superoxide dismutase; GSH, 
reduced glutathione; GSSG, oxidised glutathione; 
GSH-P, glutathione peroxidase; GSH-R, glutathione 
reductase; *OH, hydroxyl radical; R*, secondary radical;
Vit E, vitamin E; Vit £\ vitamin E radical
reactive hydroxyl radical is catalysed by free transition 
metal ions (Iron or copper) via the Haber-Weiss reac­
tion [8 13], This hydroxyl radical rapidly reacts at first 
encounter with e.g. lipids, proteins or DNA, often 
causing molecular and cellular damage [17 18].
An important intra- as well as extracellular anti-oxi­
dant or radical scavenger is vitamin E (a-tocopherol) 
[19]. It reacts with peroxyl and alkoxy radicals, there­
by preventing reaction with other molecules. The 
ensuing a-tocopherol radical is only poorly reactive 
and ends the radical chain reaction.
Other important extracellular free radical scaven­
gers which are not shown in this figure are P-caro- 
tene, ascorbate and urate [13 20]. In addition, several 
proteins (transferrin, caeruioplasmin, metallothio- 
nines) inhibit formation of reactive species by strongly 
binding iron or copper [13 21 22],
Oxidative stress is the result of a disturbance in the 
balance of the naturally generated oxidants and anti­
oxidants. This can be caused by an increase in the 
production of ROS and/or a decrease in the activity of 
anti-oxidant systems.
Malaria and oxidative stress
Production of ROS in malaria
During a malaria infection oxidative stress is increased 
by the increased production of ROS, both intra-eryth- 
rocytic and outside the parasitised erythrocyte.
Parasitised erythrocyte
Several studies report on the Increased oxidative 
stress in isolated infected red blood cells (IRBC). H20 2 
production is reported in P. herghei-IRBC, and ¿ 2*" 
production in P. falciparum-IRBC [12 23]. In P. berghei- 
and P. chabaudi-IRBC increased levels of lipid peroxi­
dation have been demonstrated [24]. It is suggested 
that ROS are produced as a result of the oxidation 
and degradation of ingested haemoglobin in the acid 
environment of the parasite's food vacuole. 
Acidification of the lysate in P. falciparum-infected 
erythrocytes (which also occurs during the digestion 
of host cell cytosol in the acid food vacuole of the par­
asite) results in the generation of H20 2 [25]. This is 
probably produced during the auto-oxidation of 
oxyHb to metHb [26]. Intact trophozoite-lRBC pro­
duce H20 2 and OH radicals about twice as much as 
normal erythrocytes, while no increase is detected at 
the ring stage when Hb-breakdown is limited. In the 
presence of reducing agents like ascorbate, extracts 
from parasitised erythrocytes caused a dose and time 
dependent DNA degradation [27]. These results sug­
gest a progressive increase in intracellular iron levels 
during the further development of P. falciparum-IRBC. 
This leads to an increased production of H20 2 and 
OH radicals can be formed that may cause molecular 
and cellular damage [28].
Extra-erythrocytic production  
Besides an enhanced intra-erythrocytic oxidative 
stress, increased production of ROS has also been 
observed outside the parasitised erythrocyte. 
Kharazmi et al. [10] demonstrated the capability of P. 
falciparum merozoites and soluble parasite antigens 
to generate ROS from blood monocytes and neu­
trophils of the host. Several in vivo studies showed
that during a P. falciparum infection ROS production 
by phagocytic cells was strongly increased and a 
more enhanced production was seen in severe and 
complicated infection than In milder cases [29 30J. 
During acute P, knowlesi infection in rhesus monkeys 
the #OH production by monocytes was considerably 
elevated [11].
Malaria parasites and effects of ROS
ROS and the defense against malaria parasites 
During the work on the establishment of continuous 
cultures of asexual biood forms of malarial parasites, it 
became clear that malarial parasites only tolerate veiy 
little oxygen in vitro and that they were sensitive to 
oxidant stress [31]. Other indications that parasites 
are sensitive to oxidative stress came from observa­
tions that certain genetic disorders, like sickle cell dis­
ease, thalassaemia and glucose-6-phosphate dehy­
drogenase deficiency (G6PD-deficiency), commonly 
found in some tropical areas, relatively protect against 
malaria. Alterations in haemoglobin-structure or the 
deficiency of the enzyme G6PD make red blood cells 
more susceptible to oxidative stress. This creates at 
the same time an unfavourable environment for the 
intra-erythrocytic parasite [32-34],
These findings lead to the research of analysis of the 
oxidative stress and the redox status of malaria-infect­
ed erythrocytes. This subject was summarised recent­
ly [12 35].
ROS, produced by activated monocytes, probably 
play an important role in the control of the parasitae- 
mia. It has been demonstrated that phagocytic cells, 
like monocytes and polymorphonuclear cells (PMNs) 
damage the intra-erythrocytic parasites by their pro­
duction of ROS [36 37]. Activated neutrophils and 
blood monocytes in vitro, are able to partially inhibit 
maturation of P. falciparum [38] and damage the 
erythrocyte membrane [39]. An increase in lipid per­
oxidation and sensitivity to hemolysis normally occurs 
during parasite maturation.
Defense o f the malaria parasite against ROS 
An important question is the way the parasite deals 
with oxidative stress. There are two possibilities; one, 
the parasite must develop its own defense, and two, 
stimulate that of the host cell to its own advantage. 
The essence of the defense is found in naturally occur­
ring anti-oxidant systems.
As described in Figure 1, GSH and NADPH support 
the scavenging of ROS. Parasites have GSH-reductase 
activity, but little is known about GSH synthesis in the 
parasite [40 41]. In parasites, growing in glucose-6- 
phosphate dehydrogenase deficient -erythrocytes 
that were infected with P. falciparumf no GSH could 
be detected [42]. This implies that in infected eryth­
rocytes the parasite may be totally dependent on host 
cell GSH synthesis. In patients infected with P. vivax, 
erythrocytic GSH and GSH-reductase activity 
decreased in proportion to the severity of the parasi- 
taemia [43]. In a murine P. berghei infection, GSH can 
only be maintained in the reduced form with NADPH 
of the host cell [44]. The hexose monophosphate 
shunt activity, which provides NADPH, is increased in 
infected erythrocytes [35]. Whether parasites have 
their own hexose monophosphate shunt remains 
unclear. In addition, the parasite possesses both gluta-
mute dehydrogenase and isocitrate dehydrogenase 
which also produce NADPH [45].
Another important anti-oxidant enzyme is SOD. 
Endogenous SOD activity has been observed in three 
different rodent malaria parasites, P. berghei, P. yoelii 
and P. vinckei [46]. P. falciparum is also capable of pro­
ducing SOD, however there is evidence that SOD 
produced by the host is "adopted" by the parasite 
[25 47]. The concentration of catalase increases in 
both the host and parasite compartment during P. fcil - 
ciparum infection [25]. H20 2 produced by the para­
site during digestion of host cell cytosol, appeared to 
be partially handled by host catalase.
Other proteins that might play a role in the oxidant 
defense of malaria parasites are histidine-rich proteins 
(HRP) [48-49 50]. HRP are found in the knobs on the 
surface of P falciparum-parasitised erythrocytes which 
are associated with the adherence to endothelial cells, 
but other functions of HRP have been proposed [51]. 
Histidine is an effective ’ OH scavenger and an effi­
cient chelator of copper and iron [52]. In addition, 
histidine forms a tight complex with H20 2 [53]. All 
together these pathways reduce the exposure of the 
parasite and its host cell to the damaging effects of 
free radicals.
The host and the effects of ROS (cerebral malaria) 
About one to two million patients each year, mainly 
children, die because of the complications of an infec­
tion with P. falciparum. The most prominent syn­
drome is cerebral malaria (CM). The clinical definition 
of CM in humans is the presence of P falciparum para­
sites in the circulation and irrecoverable coma not 
explained by any other cause [4], Post mortem, CM is 
characterised by the sequestration of parasitised 
erythrocytes (PE) in the microvasculature of the brain 
and the presence of petechiae and ring-haemorrhag- 
es, particularly in the white matter. The pathogenesis, 
however, is not yet completely understood. Most 
observations came from animal models, especially P. 
berghei infections in mice. As in human CM, cerebro­
vascular pathological changes (endothelial cell dam­
age and petechiae) and sequestration of cells in post­
capillary venules have been observed in rodent mod­
els of CM [54-56]. A striking difference between 
human and murine CM is the type of cell that seques­
ters; PE in human CM as composed to leukocytes in 
murine CM, although some reports mention also the 
sequestration of leukocytes in human CM [57]. In 
general, two hypotheses are put forward to explain 
the pathogenesis of cerebral malaria.
Erythrocyte adhesion and sequestration 
The oldest of the two hypotheses is the mechanical 
hypothesis which focuses on the sequestration of 
infected red blood cells and the blockade of the cere­
bral microvasculature [5 58]. PE express a receptor on 
their surface, Plasmodium falciparum erythrocyte 
major protein 1 (PfEMPl), which mediates the adher­
ence of PE to the endothelial lining of the postcapil- 
lary venules of several organs [59-61]. Parasitised 
erythrocytes are able to bind to a number of adhe­
sion molecules of endothelial cells, particularly of 
post-capillary venules (e.g. CD36, thrombospondin, 
intercellular adhesion molecule-1 (ICAM-1), vascular 
adhesion molecule-1 (VCAM-1) and endothelial leu­
kocyte adhesion molecule-1 (ELAM-1)) [62]. This is
supposed to cause vascular blockade, resulting in 
anoxia, acidosis and ischaemia. However, in addition 
to the mechanical obstruction of the venules, other 
factors seem to be required to induce the severe dam­
age of the endothelial lining seen in CM [5].
Immunopathology and cytokines 
A second concept is the inflammatory hypothesis, 
which is based on parasite-induced immunopatholo- 
gy [63]. In rodents, T-cells and macrophages play an 
important role in the immunopathology of CM. No 
CM occurs in congenital T-cell deficient mice or in 
normal mice treated with anti-T-cell antibodies [64- 
66]. A timely depletion of macrophages also prevents 
the development of the cerebral syndrome [67-69]. 
Malaria parasites are able to activate T-cells and 
mononuclear phagocytes to release cytokines. Of 
these cytokines, TNF (tumour necrosis factor) seems 
to be the most important in the pathogenesis of CM 
[70]. Both in human and murine CM, high TNF levels 
are associated with CM and/or severity of the disease 
[69 71-73]. Grau et at. [74] were able to prevent 
death from CM in their mouse model (P. berghei- 
Anka) by treatment with anti-TNF antibodies.
TNF can induce several changes in endothelial cells, 
like the enhanced expression of endothelial cell recep­
tors such as ICAM-1, VCAM-1 and ELAM-1 [62 75]. 
Parasitised erythrocytes bind to endothelium in vitro 
and the seventy of a P. falciparum infection is related 
to the degree of adherence of PE to the host's vascular 
endothelium [76].
Furthermore, TNF as well as lymphokines like inter­
feron gamma (IFN-y) can prime leukocytes to release 
ROS [77 78]. At the same time, iron chelators and 
phenolic radical scavengers can inhibit TNF-release 
from macrophages [79]. This suggests that oxidant 
stress can amplify TNF-induced pathology, part of 
which can be mediated by ROS. During a P. falcipa - 
rum infection an increased generation of ROS is 
observed. This explains both the role of TNF and of 
free radicals as important aspects of malaria patholo­
gy*
ROS produced by activated monocytes inhibit the 
growth of intra-erythrocytic parasites. However, the 
damaging effects of the ROS will not be limited to 
the PE since they also affect other host tissues. As 
described above, PE and leukocytes sequester in the 
brain. Local activation of T-cells and mononuclear 
phagocytes by parasite antigens and soluble products 
(malaria toxins) can result in an excessive production 
of cytokines, like TNF and ROS, which may damage 
the cerebral microvascular endothelium [5]. An 
increase in cerebrospinal fluid protein and lipid perox­
idation products in patients with cerebral malaria 
compared to controls and in fatal cases of cerebral 
malaria compared to non-fatal cases has been 
observed [80].
ROS and endothelial damage
The role of neutrophil-derived ROS in endothelial 
damage has been extensively studied. Endothelial 
damage in the rat, initiated by e.g. immune complex­
es, can be prevented by depleting animals of neu­
trophils, or by infusing SOD or catalase, radical scav­
engers or iron chelators (reviewed in [81]). These 
results suggest that *OH formation via iron and H20 2 
is involved in endothelial damage. The protective
effect of iron chelation by desferrioxamine (DFO) on 
neutrophil-mediated killing of endothelial cells, is 
associated with the presence of DFO in the endothe­
lial cells [82].
As mentioned before, an increase in redox-active 
iron may occur in malaria during the growth of P. fal - 
ciparum because of the degradation of host cell hae­
moglobin. Also, an excess of free haemoglobin (nor­
mally bound to haptoglobin and cleared by the reti- 
culo-endothelial system) might be able to catalyse the 
reduction of H20 2 to the'OH.
Additional evidence for the role of oxygen-derived 
free radicals in brain injury, comes from ischaem­
ic/reperfusion studies. In CM, the microvasculature is 
blocked with PE and periods of ischaemia and reper­
fusion might occur. Chan et al. [83], propose a role 
for hypoxanthine and xanthine oxidase in the reduc­
tion of reperfusion oxygen to 0 2#' and H20 2. In the 
presence of transition metals like iron, hydroxyl radi­
cals are formed which may stimulate peroxidation of 
membrane lipid in the brain. The iron chelator DFO 
appears to reduce brain injury in neonatal rats with 
hypoxic-ischaemic brain injury [84]. High DFO con­
centrations were achieved in the brain which might 
however protect the brain by other mechanisms than 
the chelation of iron [84 85].
Effects of experimental manipulation of the 
ROS status
Thus ROS are involved both in the control of the para- 
sitaemia and in the pathogenesis of CM. This may 
have implications for the development of drug-treat- 
ment of malaria and its cerebral complication.
administration of butylated hydroxyanisole (BHA), a 
well-known radical scavenger in vitro and in vivo, or 
the enzymes superoxide dismutase and catalase could 
prevent cerebral malaria in a murine model. After
or no cerebral symptoms and an important reduction 
in the development of haemorrhages, mononuclear 
infiltration and oedema in the CNS. Similarly, but 
more consistently protective effects were seen after 
repeated injections of BHA or by sustained release of 
BHA from osmotic pumps. The combination of intra­
venously administered polyethylene-glycol (PEG)- 
superoxide dismutase or PEG-catalase also protected 
mice against death from cerebral complications. 
Administration of two other anti-oxidants, vitamin E 
and trolox, partially protected against cerebral malar­
ia.
Chelation of iron, a very important catalyst in oxid­
ising processes, is another potential strategy to influ­
ence the development of CM. The iron chelator DFO 
might protect the central nervous system from 
ischaemic and haemorrhagic toxicity mediated by 
free radicals and especially hydroxyl radicals. DFO 
was added to a standard therapy with quinine and 
sulfadoxine-pyrimethamine to children with CM [93]. 
In the DFO group the rate of recovery to full con­
sciousness was increased compared to the placebo 
group. The difference was more pronounced among 
patients with deep coma. The rate of parasite clear­
ance from the blood was higher in the DFO treated 
group. However, DFO treatment did not prevent 
mortality. A larger clinical trial was recommended to 
determine the usefulness of DFO treatment in 
patients with CM.
Manipulation with xenobiotics
Enhanced stress w ith pro-oxidants or anti-oxidant 
inhibitors
Several investigators used the susceptibility of malaria 
parasites to oxidative stress in administering pro-oxi­
dants to try to inhibit infection. In vitro and in vivo 
studies show that agents known to generate ROS, like 
alloxan [86 ] and tert-butyl hydroperoxide [87], are 
able to inhibit Plasmodium development. Hunt and 
Stocker [12] reviewed the effects of pro-oxidants on 
different species of Plasmodia. The above mentioned 
compounds are however too toxic for human use. 
The artemisinin derivatives discussed below, are 
examples of drugs acting by this principle [88-90].
Another strategy by which oxidative stress on the 
parasite can be increased was explored by Zhang et 
al. [91]. They work on the development of inhibitors 
of anti-oxidant enzymes, thus decreasing anti-oxidant 
defenses and increasing oxidant stress. The two glu­
tathione reductase inhibitors 1,3-bis(2-chloroethyl)-1- 
nitrosourea (BCNU) and 1-(2-chloroethyl)-3-(2- 
hydroxyethyl)-1-nitrosourea (HeCNU) were tested in 
vitro. Both compounds were able to inhibit the 
growth of P. falciparum in culture. Again, these types 
of compounds are useful in experimental pharmacol­
ogy but are too toxic for human use.
Effects o f anti-oxidants
Anti-oxidants may have a protective effect against the 
unwanted effects of ROS on the integrity of the vascu­
lar lining. Thumwood et al. [92] described that
ROS and food components
Several investigators investigated the control of 
malaria by dietary manipulation. Important food 
components in controlling dietary-induced oxidative 
stress are unsaturated fatty acids (pro-oxidants), vita­
min C (ascorbic acid, pro- and anti-oxidant effects) 
and vitamin E (tocopherol, anti-oxidant).
Food components and parasitaemia 
Vitamin E deficient mice are protected against P, yoelii 
infection with diets containing fish oil. Dietary vitamin 
E supplementation enhanced the infection and killed 
the mice [94], Protection was also seen in chloro- 
quine-resistant malaria in mice after feeding a vitamin 
E-deficient diet supplemented with menhaden-fish oil 
[95]. Addition of menhaden or fish oil to a normal 
chow diet had a strong, but incomplete, protective 
effect in normal mice against P, yoelii and P, berghei 
infection respectively [96 97].
Dietary supplementation with highly unsaturated 
fatty acids of fish oils results in the incorporation of 
these substances into the host erythrocyte and/or 
parasite membranes. In the absence of vitamin E, 
such membranes would be very vulnerable to oxida­
tive stress. In an experimental set up it might be pos­
sible to decrease the vitamin E content of the host 
plasma sufficiently to block the erythrocytic stage of 
the parasite, without depleting the tissue tocopherol 
stores and running the risk of serious side effects [98]. 
A severe or absolute vitamin E deficiency might not 
be required to obtain full protection against the para­
site. in many areas where malaria is endemic, the vita-
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min E status of the population is low. 
Supplementation with highly unsaturated fatty acids 
could be of some benefit against malaria.
Addition of unsaturated tropical (plant) oils to a 
vitamin E deficient diet did not protect against a P. 
berghei infection in mice [98]. This can be explained 
by the fact that fish oil contains much more polyun­
saturated fatty acids than tropical plant oil. Thus, not 
only is the vitamin E status important, but also the 
peroxidisability of the dietary fatty acids incorporated 
in membranes. However, the exact biochemical 
mechanism by which unsaturated fatty acids act 
remains unclear. Certain prostaglandin derivatives 
decrease the growth of malarial parasites in mice 
[99], so an effect offish oil in modulating prostaglan­
din metabolism must be considered. At the same 
time, vitamin E-deficiency alone can also have an 
antimalarial effect in mice [100],
Vitamin C with its well-known anti-oxidant effects 
can also exert strong pro-oxidant effects in the pres­
ence of metals such as iron or copper [98]. Ascorbic 
acid treatment marginally enhanced the develop­
ment of young parasites, but was highly deleterious 
to advanced forms of P. falciparum [101 ]. This deleter­
ious effect on late stage parasites is probably due to 
its pro-oxidant action that synergises with increased 
levels of iron-containing structures, that are produced 
during growth and differentiation of the parasite. 
Until now, no effect of dietary supplementatiqn of 
vitamin C on the course of malaria infected mice has 
been observed.
Food components and protection against CM 
The effects of dietary supplementation or restriction 
were not only studied in the course of infection but 
also in development of CM. Anti-oxidants are expect­
ed to protect against the vascular complications of 
malaria.
Dietary-induced oxidative stress has recently been 
demonstrated to protect against CM in a murine 
model [102]. Mice were fed a diet, supplemented 
with menhaden-fish oil and deficient of vitamin E for 
four weeks before and during infection with P berghei 
ANKA. Mice receiving this diet showed complete sur­
vival for 14 days post infection and 6-day parasitaemi- 
as were decreased. The antimalarial effect could be 
prevented by supplementing the diet with vitamin E 
or with either of two synthetic anti-oxidants, N.N'- 
diphenyl-p-phenylenediamine or probucol. These 
results contradict with the studies in which anti-oxi­
dant treatment results in protection against CM [92]. 
Different cytokines (IL-1, TNF) may play a mediatory 
role in the prevention of CM following administration 
of diets supplemented with fish-oil and deficient of 
vitamin E [97 103 104]. However, the exact mecha­
nism is not clear yet.
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New drugs, acting on oxidative stress
Glutathione reductase is an important intracellular 
anti-oxidant enzyme. The structure of the enzyme is 
known, and appears to be an interesting target for 
the design of novel antimalarial drugs. Zhang et al. 
[91] disturbed the pro-oxidant-anti-oxidant balance 
in favour of the former by the administration of glu­
tathione reductase inhibitors. What is important is the 
fact, that glutathione reductase is not essential for the
normal function of the erythrocytes. Inhibitors must 
act preferentially in the infected erythrocyte without 
affecting normal function of other host tissues.
Promising new antimalarial drugs are artemisinin 
(qinghaosu) extracted from the leaves of Artemisia 
annua L and its derivatives [88 89]. Artemisinin and its 
derivatives artemether (an oil-soluble methyl ether) 
and artesunate (a sodium succinyl salt) are produced 
for clinical use in several countries. The results of com­
parative studies in which a qinghaosu compound was 
compared with another antimalarial, show a reduc­
tion of the fever clearance time (17% ~ 7.7 h) and of 
the parasite clearance time (32% -  19.8 h) for the 
qinghaosu compound, but also a higher recrudes­
cence rate (reviewed in [1 0 5 ]) .  These compounds 
play a role in the treatment of severe malaria. Maeno 
et al. [1 0 6 ]  studied the effects of artesunate on rhesus 
monkeys experimentally infected with Plasmodium 
coatneyi. They found in addition to a reduced parasi- 
taemia, a reduced rate of sequestration of PE in cere­
bral microvessels.
The endoperoxide bridge of these compounds 
seems to be essential for antimalarial activity, and 
strong evidence exists that the antimalarial activities 
of these drugs depend on the generation of free radi­
cal intermediates that alkylate and oxidise proteins 
and oxidise lipids [107 108]. In the presence of the 
free radical scavengers ascorbic acid and vit E, the 
antimalarial activity is decreased in vitro [109 110] 
and in vivo [111]. Haem and free iron (abundantly 
present in infected red blood cells) seem to be 
responsible for the activation of the drugs and the 
selective toxicity to malaria parasites. Artemisinin is 
also activated in vitro by haem and free iron [112- 
114], while chloroquine, which binds haem, antagon­
ises the antimalarial activity [115].
Clinical perspectives in m alaria prevention 
and therapy
Despite all the efforts made, malaria is still the world's 
most devastating human infection. Since 1960, chlo- 
roquine-resistant and multidrug-resistant strains of P. 
falciparum have spread and the degree of resistance 
has increased [116]. New strategies focus on vac­
cines, life style, food habits and on development of 
new drugs.
The first malaria vaccine, SPf66, claimed some suc­
cess in several phase ll en 111 trials in Latin America as 
well as in Africa [reviewed in 117]. In Tanzania, the 
estimated vaccine efficacy against clinical malaria was 
31% while the incidence of mild side effects after 
three doses was less than 6%. There is however much 
skepticism and little reason for optimism with respect 
to the SPf66 vaccine. The second trial in the Gambia 
[118] revealed no protection by SPf66 and the results 
of a third trial in Thailand are about to become avail­
able.
The approach discussed in this review focuses on 
the oxidative stress that occurs in malaria and the 
generation by and susceptibility of malaria parasites 
to ROS. The production of ROS seems to be part of 
the natural host defense against malarial parasites and 
several investigations have tried to increase this natu­
ral defense by administration of pro-oxidants. In 
recent studies, oxidative stress was increased by the 
addition of polyunsaturated fatty acids to the diet and
indeed parasitaemia was inhibited. However, in most 
studies the diet was fed for several weeks which 
makes it a less realistic approach. In addition, ROS are 
also involved in host tissue pathology. An increase in 
oxidative stress could increase host tissue pathology.
The role of dietary restriction and supplementation 
and its significance in the treatment of cerebral malar­
ia is not yet elucidated.
ROS play a dual role in malaria. Besides their pro- 2 
tective effect agamst malarial parasites, ROS pro- 3 
duced by activated leukocytes sequestered in the 
postcapillary venules might contribute to the pathol­
ogy observed in severe and cerebral malaria. In con­
trast to pro-oxidants, anti-oxidants could play a role 
in the treatment of malaria pathology. The protective 
results obtained with the radical scavenger BHA and 
the anti-oxidant enzymes SOD and cataiase are prom­
ising.
Another promising approach could be the use of an 
iron chelation therapy. The iron chelator desferrioxa- 
mine has been available for clinical use for a period of 
time and is used in the treatment of Iron and alumi­
num overload. The discovery of the central role of 
iron in *OH production and the role of free radicals in 
many human pathologies stimulated the interest of 
many investigators for DFO [119]. In malaria, DFO 
was first shown to inhibit parasitaemia, by depriving 
the parasite's enzymes (e.g. ribonucleotidase) of 
essential iron [120-122]. In addition, DFO might also 
protect against cerebral damage by chelating iron 
and thus inhibiting hydroxyl radical formation. A 
major disadvantage of DFO is its low gastrointestinal 
absorption and penetration into cells. The therapeutic 
efficacy of iron chelators might be increased by the 
development of new, oral iron chelators which are 
able to penetrate cells more easily.
As stated before, a major problem in the treatment 
of malaria is the development of resistance of the par­
asite to most drugs. Most current antimalarial drugs 
like chloroquine, were developed on the basis of their 
action against asexual erythrocytic forms of malaria 
parasites, which are responsible for clinical illness 
[123 124]. Primaquine is the only drug clinically used 
to eradicate tissue forms of plasmodia that cause 
relapses. Compounds that are being used against 
chloroquine-resistant and multidrug-resistant strains 
of P. falciparum include mefloquine and halofantrine.
Both compounds are related to quinine.
New important drugs, acting by increasing the oxi­
dative stress and clinically tested at present are the 
artemisinin-derivatives as discussed above. A promis­
ing class of drugs might be derived in the future from 
the glutathione reductase inhibitors, as discussed 
above.
It is reasonable to assume that new antimalarials, 
including pro-oxldants, that act upon the parasite will 
eventually induce resistance. This is not true for com­
pounds not acting upon the parasite, but preventing 
host pathology in another way, like anti-oxidants 
could do on the vascular complications. A second 
advantage could be that by preventing pathology, 
the patients own immune-system might be able to 
overcome the infection, leading to development of 
immunity to the parasite. If we consider new strate- 27 
gies in the prevention and treatment of malaria based 
on the oxidative stress that occurs in malaria, sub- ^  
stances that can efficiently bind or deplete intracellu-
lar Fe3+ should be highly considered in the treatment 
of severe disease.
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